Kelun-Biotech’s sac-TMT combination cuts progression or death risk 51% in Phase III lung cancer trial

• Kelun-Biotech's Phase III OptiTROP-Lung06 trial showed sacituzumab tirumotecan with pembrolizumab delayed disease progression versus chemotherapy with pembrolizumab.
• The study evaluated first-line treatment for advanced non-squamous non-small cell lung cancer without EGFR/ALK alterations or PD-L1 expression.
• Responses lasted longer with the experimental combination. Overall survival showed a trend toward improvement.
• The combination caused fewer severe adverse events and fewer treatment discontinuations than the chemotherapy regimen, with no new safety signals.
• Results announced Oct. 25, 2026, were already presented at ESMO and simultaneously published in The New England Journal of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN79690) on October 25, 2026, and is solely responsible for the information contained therein.